P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE

Therapeutic innovation in multiple myeloma (MM), through the sequential integration of immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cellular therapies, and bispecific antibodies, has significantly improved survival outcomes. Alongside novel agents and combinations, optimize...

Celý popis

Podrobná bibliografie

Hlavní autoři:	G. Giunta, C. Bellofiore, E. Scalisi, F. Elia, B. Garibaldi, C. Finocchiaro, F. Di Raimondo, A. Romano, C. Conticello
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2026-04-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/14086
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!